APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Other Events
Item 8.01 Other Events.
On December 2, 2020, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing that it has expanded its ADAPTIR bispecific technology to include a new multi-specific platform technology, ADAPTIR-FLEX™. The Company also announced that it has developed a new bispecific candidate, APVO442, that uses ADAPTIR-FLEX platform technology. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Aptevo Therapeutics Inc. Exhibit
EX-99.1 2 apvo-ex991_6.htm EX-99.1 apvo-ex991_6.htm EXHIBIT 99.1 For Immediate Release APTEVO THERAPEUTICS ANNOUNCES THE LAUNCH OF ITS SECOND PLATFORM TECHNOLOGY ADAPTIR-FLEXTM AND INTRODUCES THE NEW BISPECIFIC PROSTATE CANCER CANDIDATE APVO442 New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform Technology APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer Seattle,…
To view the full exhibit click
About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).